Autoimmune Hemolytic Anemia
Immunology·MeSH: Anemia, Hemolytic, Autoimmune
Prevalence
5.0 / 100K
6 drugs in development·5 companies·4 clinical trials
Drug Pipeline by Phase
Phase 3(4)
Phase 1(1)
| Drug | Company |
|---|---|
| CTX112 | CRISPR Therapeutics AG (CRSP) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| zugo-cel | CRISPR Therapeutics AG (CRSP) |
Compare drugs
Frequently asked questions
How many drugs are in development for Autoimmune Hemolytic Anemia?
BioSniper tracks 6 drugs in development for Autoimmune Hemolytic Anemia across 5 companies.
How many clinical trials target Autoimmune Hemolytic Anemia?
There are 4 clinical trials targeting Autoimmune Hemolytic Anemia tracked by BioSniper.
What is the prevalence of Autoimmune Hemolytic Anemia?
The estimated prevalence of Autoimmune Hemolytic Anemia is approximately 5.0 per 100,000 population.
Deep-dive into Autoimmune Hemolytic Anemia
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis